Lead development candidate AGTC-501, is a gene therapy program in Phase II clinical trials for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in boys and young men.
David Fellows, CEO
Consilium Strategic Communications:
Alex Harrison, Ashley Tapp
Tel: +44 (0)20 3709 5700
About Beacon Therapeutics
Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to restore and improve
the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
The Company has an established scientific foundation that combines a late–stage development
candidate to treat X–linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one
targeting dry age–related macular degeneration (AMD) and another in–licensed from the University of
Oxford targeting cone–rod dystrophy (CRD), an inherited retinal disease.
Lead development candidate AGTC–501, is a gene therapy program in Phase II clinical trials for the
treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in
boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase
regulator (RPGR) gene. AGTC–501 expresses the full length RPGR protein, thereby addressing the full
complement of photoreceptor damage caused by XLRP, including both rod and cone loss.
Beacon Therapeutics also has access to a target generation technology platform that will identify,
screen, and search secreted proteins in the ophthalmology space.
The Company is supported by funds from Syncona and additional investors including Oxford Science
Find out more about us online at: www.beacontx.com.